Edgar Filing: OncoMed Pharmaceuticals Inc - Form 4

OncoMed Pharmaceuticals Inc Form 4 October 03, 2014

October 03, 2	2014										
FORM 4 UNITED STATES SECURITIES AND EXCHANCE COMMISSION										OMB APPROVAL	
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549									OMB Number:	3235-0287	
Check this		anigun, D.C. 2004)					Expires:	January 31			
if no long subject to Section 16 Form 4 or Form 5		CHANGES IN BENEFICIAL OWN SECURITIES ection 16(a) of the Securities Exchange						Expires: 200 Estimated average burden hours per response 00			
obligation may conti <i>See</i> Instru 1(b).	nue. Section 17(a		ic Uti	lity Hold	ing Com	ipany	Act of	f 1935 or Sectio	n		
(Print or Type R	esponses)										
1. Name and Address of Reporting Person * 2. Issuer Lewicki John A. Symbol OncoMe [OMED]				r Name and Ticker or Trading				5. Relationship of Reporting Person(s) to Issuer			
					ceutical	s Inc		(Check all applicable)			
(Last) (First) (Middle) 3. Date of (Month/Da				f Earliest Transaction Day/Year)				Director 10% Owner X Officer (give title Other (specify below) below)			
C/O ONCOM PHARMACI CHESAPEA	EUTICALS, INC		02/20	14				· · · · · · · · · · · · · · · · · · ·	nief Scientific (Officer	
				ndment, Date Original th/Day/Year)				6. Individual or Joint/Group Filing(Check Applicable Line) _X_ Form filed by One Reporting Person			
REDWOOD	CITY, CA 9406	3							More than One Re		
(City)	(State) (Zip)	Table	I - Non-De	erivative S	Securi	ties Acq	quired, Disposed o	f, or Beneficial	lly Owned	
1.Title of Security (Instr. 3)2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)				3.4. Securities Acquired Transaction(A) or Disposed of CodeCode(D) (Instr. 8)(Instr. 3, 4 and 5)				5. Amount of Securities Beneficially Owned Following Reported Transaction(s)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)		
				Code V	Amount	or (D)	Price	(Instr. 3 and 4)			
Common Stock	10/02/2014			M <u>(1)</u>	5,809	А	\$ 1.43	26,411 <u>(2)</u>	D		
Common Stock	10/02/2014			S <u>(1)</u>	5,809	D	\$ 20	20,602 <u>(2)</u>	D		
Common Stock								82,928	Ι	See Footnote (3)	

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transactia Code (Instr. 8)	Transaction Derivative Code Securities		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Underlying Securities (Instr. 3 and 4)	
				Code V	(A) (D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	
Stock Option (Right to Buy)	\$ 1.43	10/02/2014		M <u>(1)</u>	5,809	<u>(4)</u>	01/11/2017	Common Stock	5,809	

Reporting Owners

Reporting Owner Name / Address		Relationships					
	Director	10% Owner	Officer	Other			
Lewicki John A. C/O ONCOMED PHARMACEUTICALS, INC. 800 CHESAPEAKE DRIVE REDWOOD CITY, CA 94063			EVP & Chief Scientific Officer				
Signatures							
/s/ Alicia J. Hager, Attorney-in-Fact for John A. Lewicki	10/03/2014						
**Signature of Reporting Person		Date					
Explanation of Responses:							
* If the form is filed by more than one reporting person, see	e Instructio	n 4(b)(v).					

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

- (1) Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on May 13, 2014.
- (2) Includes 20,000 restricted stock units. The Reporting Person is entitled to receive one (1) share of common stock for each one (1) restricted stock unit.
- (3) The shares are held by John Allan Lewicki and Jenniffer Joan Lewicki, Trustees of the Lewicki Family Trust dated December 6, 2000.

(4)

The option is fully vested and exercisable, subject to an annual limitation of 175,438 shares that can be issued to a single grantee upon the exercise of awards under the Issuer's 2004 Stock Incentive Plan.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.